Professor Jonathan Williams, one of the UK’s leading organic chemists, has received a Royal Society Wolfson Merit Award for his research.
Williams, from the University of Bath’s Department of Chemistry, is the recipient of a £10,000 a year award over a five-year period. The award will fund his research group’s work in designing metal catalysts for new chemical reactions.
In many cases, the metal catalysts developed by the group allow reactions to be more environmentally friendly because molecules can be constructed more efficiently and use less energy.
Professor Paul Raithby, Head of the Department of Chemistry, said: ‘Jonathan is undoubtedly one of the most creative and productive organic chemists of his generation in the UK. His work has influenced academic chemistry internationally, as well as having had significant impact in industrial practice.
‘Jonathan has attracted a talented group of organic chemists to Bath and we are determined to support him in further developing the department’s international reputation as a leading centre for catalysis and chemical synthesis. This award is a significant contribution to that goal.’
Until recently, the research group worked on a method of constructing chemical bonds using catalytic reactions that they termed ‘Borrowing Hydrogen Methodology’. This focused on the metal catalyst temporarily removing hydrogen from the starting material, allowing it to react more easily.
Williams said: ‘The resulting compounds from this technique are made more cleanly than they would be traditionally. Using our methodology, the only by-product created is water, and there is no need to use carcinogenic starting materials.’
The group has since changed its focus and the Wolfson Merit Award will fund research into new catalytic reactions.
‘We’re now focusing on developing new approaches to the formation of amides, the chemical bonds found in proteins, in many drug molecules, and in robust materials such as Nylon and Kevlar,’ said Williams.
‘This new research will aim to identify catalytic methods for the formation of amides, which are traditionally prepared using cumbersome, inefficient chemistry.’
Bath professor receives Wolfson Merit Award
The award will fund Jonathan Williams\' research into metal catalysts for new chemical reactions
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Research & Development
Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development
The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
Research & Development
Biognosys collaborates with Michael J. Fox Foundation to develop biomarker assays for Parkinson's research
The pair will work to develop highly sensitive, quantitative biomarker assays targeting LRRK2, the most common genetic risk factor for late-onset Parkinson's disease, in support of the foundation's global LITE initiative spanning more than 50 academic, industry and clinical partners